Retatrutide Structure and Triple Agonism at GLP-1R, GIPR, and GCGR

For research use only. This reference describes retatrutide strictly as a chemical compound used in cell-based receptor pharmacology and animal research. Research-grade retatrutide is not equivalent to, and is not a substitute for, any FDA-approved pharmaceutical product of a similar name. Nothing here is intended for human or animal consumption. We make no health, performance, or therapeutic claims of any kind. For full context, see our research-use disclaimer.

Retatrutide — development code LY3437943, sometimes referenced under sponsor program names — is a synthetic 39-amino-acid peptide built on a glucose-dependent insulinotropic polypeptide (GIP) backbone. It engages three Class B G-protein-coupled receptors as an agonist: the glucagon-like peptide-1 receptor (GLP-1R), the GIP receptor (GIPR), and the glucagon receptor (GCGR). What follows covers the peptide's primary structure, the three non-coded residues that give it protease resistance and receptor-tuned activity, the cryo-EM evidence for how a single continuous α-helix engages all three receptors, the comparative receptor-level potency profile, the structural class it belongs to, and the current regulatory picture for laboratories ordering material.

Primary structure: a 39-residue GIP-derived peptide

Retatrutide's chemical identity sits in well-defined territory for an actively-investigated peptide. The compound is documented in encyclopedic references and in the structural literature as a synthetic 39-amino-acid sequence built on a GIP backbone. The 2024 Cell Discovery cryo-EM paper by Sun and colleagues resolves its structure bound to each of the three target receptors and is the primary reference for the architectural details that follow.

Why a GIP backbone

The choice of starting backbone is itself informative. Among the three target receptors, the GIP receptor is the most divergent from native GLP-1 in the binding-pocket details that matter for ligand recognition. Designing from a GIP-derived sequence makes triple-receptor engineering more tractable than starting from GLP-1: the harder selectivity problem is closer to solved at the outset, and the easier modifications fall on the GLP-1R and GCGR ends. Several other multi-receptor peptide programs have made the same backbone choice for the same reason.

Lipidation at Lys17

The peptide is acylated at lysine 17 with a C20 fatty diacid moiety connected via a γGlu-2×OEG linker. That fatty diacid enables high-affinity, reversible binding to serum albumin — the structural mechanism behind the long pharmacokinetic half-life shared with other once-weekly peptide agonists in the same structural class. The lipidation strategy is older than retatrutide. It was first demonstrated in earlier-generation peptide drugs and has since become a standard tool for tuning the half-life of large therapeutic peptides without changing their receptor pharmacology.

Engineered modifications: three non-coded residues

Three positions in retatrutide carry non-canonical amino acids — α-aminoisobutyric acid (Aib) at positions 2 and 20, and α-methyl-L-leucine (αMeL) at position 13. Each one earns its place for a specific structural reason.

Aib2 — protease resistance

Native GLP-1 and GIP get cleaved at their N-termini by dipeptidyl peptidase 4 (DPP-4). The enzyme cuts between residues 2 and 3 in both peptides. Aib at position 2 introduces backbone constraints that the DPP-4 active site can't accommodate, and the cryo-EM analysis confirms that Aib2 is the principal structural feature behind the molecule's DPP-4 resistance — the same modification has been used in other Class B GPCR peptides for the same reason.

αMeL13 — GIP-receptor activity

α-methyl-L-leucine at position 13 supports activity at the GIP receptor. α-methyl substitution at chiral centers is a common medicinal-chemistry technique: it locks side-chain orientation against the protein binding surface and reduces conformational entropy on binding. In retatrutide, this is the single residue most credited with maintaining GIPR engagement when the rest of the sequence is tuned for the other two receptors.

Aib20 — pharmacokinetic and developability properties

The second Aib appears at position 20. Reviewers describe its contribution as overall stability and developability — a less specific change, but a useful one that supports the molecule's pharmacokinetic profile. Aib placements like this are typical of late-stage medicinal chemistry, where a small handful of substitutions can shift handling characteristics without disturbing the activity-relevant binding interface.

Receptor binding architecture

The defining structural finding for retatrutide is that one peptide engages three Class B GPCRs in essentially the same conformation. The 2024 cryo-EM paper resolves retatrutide bound to GLP-1R, GIPR, and GCGR, and the bound peptide adopts a single continuous α-helix in all three structures.

N-terminal segment: residues 1–13

The N-terminal segment penetrates the core of each receptor's seven-transmembrane bundle. This is the activation segment — the contacts that engage the conserved Class B GPCR activation machinery and trigger downstream G-protein coupling. The region is largely conserved across the three receptors, which is why the same N-terminal sequence works in all three pockets.

C-terminal segment: residues 14–30

From residue 14 onward, the peptide leaves the transmembrane core and contacts the N-terminal α-helix of the receptor extracellular domain (ECD), the extracellular tip of TM1, and ECL1. This is the selectivity segment — the contacts that vary between receptors, and the segment the medicinal-chemistry program had to balance. Without the lipidated tail beyond residue 30, the peptide would not show the receptor-recognition pattern seen in the structures.

Receptor-specific differences

Although the three structures are broadly superimposable, ECL1, ECL3, and the extracellular tips of TM1, TM3, and TM7 differ enough in side-chain packing and helical tilt to produce distinct potency profiles. These are the same regions that earlier comparative studies of dual GLP-1R/GCGR agonists — captured in the PMC review of dual-agonism structures — flagged as the variable selectivity-tuning segments. Triple agonism follows the same playbook with one more receptor in scope.

Comparative potency at the three receptors

In cell-based receptor activation assays, retatrutide doesn't reach equipotency across all three targets. The receptor-level pharmacology, summarized in the 2024 review by Doggrell, is asymmetric in a way the structural differences anticipate.

At the GLP-1 receptor

Retatrutide is reported as less potent than native GLP-1 at the human GLP-1 receptor in cell-based assays. The drop reflects the structural compromises required to retain activity at the other two receptors — the C-terminal contacts that engage GLP-1R best are not the same ones that engage GIPR or GCGR best.

At the GIP receptor

At the human GIP receptor, retatrutide is reported as more potent than native GIP. The αMeL13 modification and the GIP-derived backbone both contribute. The molecule was, in effect, engineered upward at this target.

At the glucagon receptor

At the glucagon receptor, retatrutide's activity falls between the other two. Structural differences at ECL1 and the TM1 extracellular tip in GCGR-bound retatrutide explain why the C-terminal contacts here are intermediate rather than tuned to either extreme.

What this means for assay design

Researchers running parallel-receptor cell-based assays should normalize each receptor's response against its own native ligand — not against a single common reference. Use GLP-1 alone as the reference and retatrutide will look under-active at GIPR. Use GIP alone and it will look over-active at GLP-1R. Both interpretations are misleading. The cleanest reporting practice is per-receptor EC50 with the matched native-ligand control on the same plate.

Structural class context: dual agonists and other tri-agonists

Retatrutide is one of several multi-receptor peptide agonists in active structural characterization. The framework that makes triple agonism possible is the same one earlier dual-agonist work established.

Dual GLP-1R / GCGR agonists

The comparative cryo-EM analysis of dual GLP-1R/GCGR agonists established the structural rules: conserved N-terminal contacts drive activation, and a more variable C-terminal segment tunes selectivity. Retatrutide's structures fit that pattern with the GIP receptor added as a third target rather than violating it.

Other tri-agonists in the same structural class

NN1706 is a separate triple agonist from another program, characterized in a 2025 ScienceDirect paper. NN1706 makes different specific design choices — different lipidation site, different linker chemistry, different residue identities at the conserved Aib positions — but it operates in the same structural class. Reading the two programs side by side highlights that the design space for multi-receptor peptide agonists isn't unique to one solution; multiple groups have arrived at viable tri-agonists with different chemical fingerprints.

Regulatory status

No regulatory authority has approved retatrutide for human use as of 2026. The published evidence base is preclinical structural pharmacology, cell-based receptor assays, and clinical-investigation data; the compound is in late-stage trials but has not reached marketing authorization. Commercial availability is restricted to the research-chemical channel, and research-grade material sold for in-vitro work is not equivalent to and is not a substitute for any FDA-approved pharmaceutical product.

Related Optides reading

For broader context on the same compound from a different angle, see Optides' earlier retatrutide overview. For the regulatory framework that shapes how research-grade peptides are sold and handled in the United States, see our research-use legal landscape article.

Frequently Asked Questions

What is retatrutide and what does it target?

Retatrutide (development code LY3437943) is a synthetic 39-amino-acid peptide engineered from a glucose-dependent insulinotropic polypeptide (GIP) backbone. It is a triple agonist at three Class B GPCRs: the glucagon-like peptide-1 receptor (GLP-1R), the GIP receptor (GIPR), and the glucagon receptor (GCGR). Cell-based pharmacology assays show concentration-responsive activity at all three. For research use only — research-grade material is not equivalent to any FDA-approved pharmaceutical product.

What are the three non-coded residues in retatrutide and why are they there?

Retatrutide contains three non-canonical residues: α-aminoisobutyric acid at position 2 (Aib2), α-methyl-L-leucine at position 13 (αMeL13), and α-aminoisobutyric acid at position 20 (Aib20). Aib2 introduces conformational rigidity at the N-terminal cleavage site of dipeptidyl peptidase 4 (DPP-4) and is the structural source of the peptide's protease resistance. αMeL13 supports activity at the GIP receptor. Aib20 contributes to overall pharmacokinetic stability.

How does the same peptide engage three different receptors?

Cryo-EM structures show retatrutide bound to GLP-1R, GIPR, and GCGR adopts a single continuous α-helix in all three cases. The N-terminal segment (residues 1–13) penetrates the receptor transmembrane core; the C-terminal segment (residues 14–30) contacts the extracellular domain, the extracellular tip of TM1, and ECL1. The three receptor structures are broadly superimposable, but receptor-specific differences at ECL1, ECL3, and the extracellular tips of TM1, TM3, and TM7 account for the differential potency profile.

Has retatrutide been approved for human use?

No regulatory authority has approved retatrutide for human use as of 2026. The published evidence base is structural pharmacology, cell-based receptor assays, and clinical-investigation data. Research-grade material sold for laboratory work is not equivalent to and is not a substitute for any FDA-approved pharmaceutical product. Optides supplies the compound for in-vitro research only.

Conclusion

Retatrutide is a structurally well-defined 39-residue peptide. The chemistry is concrete: a GIP-derived backbone, three non-coded residues — Aib2 for DPP-4 resistance, αMeL13 for GIP-receptor activity, Aib20 for pharmacokinetic properties — and a Lys17 fatty-diacid acylation that supports albumin binding. Cryo-EM evidence shows the peptide adopts a single continuous α-helix at all three target receptors, with N-terminal contacts driving activation and C-terminal contacts driving selectivity. Receptor-specific differences in the extracellular loops and TM tips account for the differential potency profile. The compound sits in an actively expanding structural class of multi-receptor peptide agonists. For research use only.

For research use only. Not for human or animal consumption of any kind. The information in this article is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. The statements made have not been evaluated by the U.S. Food and Drug Administration. These products are NOT FDA APPROVED. Please consult with a licensed healthcare professional before making any decisions regarding your health or research.

Optides LLC is a chemical supplier. Optides LLC is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic Act. Optides LLC is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic Act.